Pancreatic Cancer Research

ResearcherCentre Hospitalier Universitaire VaudoisActive in the last 2 years

G. Deplanque

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5113797216. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 8

  1. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  2. TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Co-author DOI 10.1007/s00280-019-03807-4↗
  3. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  4. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Co-author DOI 10.1038/s41416-018-0246-z↗
  5. Pancreatic cancer: are more chemotherapy and surgery needed? Co-author DOI 10.1016/s0140-6736(17)30126-5↗
  6. Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdw607↗
  7. Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. Co-author DOI 10.1097/ftd.0000000000000399↗
  8. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv133↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Denis Pezet · 3 shared papers, 2017–2019 · strength 0.20
  2. Teresa Mercade Macarulla · 3 shared papers, 2018–2019 · strength 0.19
  3. Nicolas Demartines · 1 shared paper, 2017 · strength 0.15
  4. Karim Adnane Benhadji · 2 shared papers, 2018–2019 · strength 0.14
  5. Josep M. Tabernero · 2 shared papers, 2018–2019 · strength 0.14
  6. Rocio García‐Carbonero · 2 shared papers, 2018–2019 · strength 0.14
  7. Davide Melisi · 2 shared papers, 2018–2019 · strength 0.14
  8. Eric Van Cutsem · 2 shared papers, 2017–2018 · strength 0.11
  9. Bohuslav Melichar · 2 shared papers, 2015–2017 · strength 0.10
  10. Francesca Simionato · 1 shared paper, 2019 · strength 0.08
  11. Ivelina Gueorguieva · 1 shared paper, 2018 · strength 0.07
  12. Helmut Oettle · 1 shared paper, 2018 · strength 0.07
  13. Laëtitia Dahan · 1 shared paper, 2017 · strength 0.06
  14. Johan Gagnière · 1 shared paper, 2017 · strength 0.06
  15. Cindy Serdjebi · 1 shared paper, 2017 · strength 0.06
  16. Éric François · 1 shared paper, 2017 · strength 0.06
  17. Peter James O'Dwyer · 1 shared paper, 2017 · strength 0.06
  18. Thomas R. Jeffry Evans · 1 shared paper, 2017 · strength 0.06
  19. Gyorgy Bodoky · 1 shared paper, 2017 · strength 0.06
  20. Alexander S. Rosemurgy · 1 shared paper, 2017 · strength 0.06
  21. Franck Bonnetain · 1 shared paper, 2018 · strength 0.05
  22. Werner Scheithauer · 1 shared paper, 2018 · strength 0.05
  23. Richard Herrmann · 1 shared paper, 2018 · strength 0.05
  24. Helmut Frieß · 1 shared paper, 2018 · strength 0.05
  25. L. Bengt van Rijssen · 1 shared paper, 2018 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.